Suppr超能文献

[在二尖瓣狭窄继发肺动脉高压患者中,维拉帕米或卡托普利作用达峰值时氧气对肺动脉压无额外作用]

[Lack of additional action of oxygen on pulmonary artery pressure at the peak of verapamil or captopril action in pulmonary hypertension secondary to mitral stenosis].

作者信息

Dubiel J P, Zmudka K, Brzostek T

机构信息

I Kliniki Kardiologii, Zakładu Hemodynamiki i Angiokardiografii Instytutu Kardiologii AM, Krakowie.

出版信息

Pol Tyg Lek. 1991;46(22-23):409-11.

PMID:1669076
Abstract

The aim of the study was to investigate whether oxygen causes a further decrease in pulmonary artery pressure after administration of calcium channel blocker-verapamil-or angiotensin converting enzyme inhibitor-captopril-in the secondary pulmonary hypertension. We studied 37 patients with the secondary pulmonary hypertension (mean pulmonary artery systolic pressure = 56.1 mm Hg) due to mitral stenosis. After having completed hemodynamic diagnostic procedures, basal oxygen test was performed and pulmonary artery pressure was recorded at 10 min of oxygen breathing. Then, 10 mg of verapamil was injected into the pulmonary artery of 16 patients and 21 patients received 75 mg of oral captopril. At the peak of vasodilation, 30 min after verapamil and 90 min after captopril administration, pulmonary artery pressure was recorded and oxygen test was repeated. Baseline oxygen test produced a statistically significant decrease in pulmonary artery pressure. Verapamil and captopril also lowered pulmonary artery systolic and diastolic pressures. The second oxygen test did not cause a further decrease in the pulmonary artery pressure; mean pulmonary artery systolic pressure was 52.3 +/- 23.7 mm Hg, pulmonary artery diastolic pressure 22.7 +/- 10.6 mm Hg before and 49.1 +/- 23.8 mm Hg and 23.0 +/- 13.5 mm Hg, respectively after the test in verapamil group, and 47.0 +/- 15.5 mm Hg and 21.7 +/- 8.4 mm Hg before and 46.6 +/- 15.4 mm Hg, respectively in captopril subset. The results may support the thesis that vasodilating effect depends rather on the degree of pulmonary vascular changes than on the vasodilatory mechanism of particular drugs.

摘要

本研究的目的是调查在继发性肺动脉高压患者中,给予钙通道阻滞剂维拉帕米或血管紧张素转换酶抑制剂卡托普利后,吸氧是否会导致肺动脉压力进一步降低。我们研究了37例因二尖瓣狭窄导致继发性肺动脉高压(平均肺动脉收缩压 = 56.1 mmHg)的患者。在完成血流动力学诊断程序后,进行基础吸氧试验,并在吸氧10分钟时记录肺动脉压力。然后,16例患者经肺动脉注射10 mg维拉帕米,21例患者口服75 mg卡托普利。在血管扩张的峰值,即维拉帕米给药后30分钟和卡托普利给药后90分钟,记录肺动脉压力并重复吸氧试验。基础吸氧试验使肺动脉压力有统计学意义的降低。维拉帕米和卡托普利也降低了肺动脉收缩压和舒张压。第二次吸氧试验并未导致肺动脉压力进一步降低;维拉帕米组试验前平均肺动脉收缩压为52.3±23.7 mmHg,肺动脉舒张压为22.7±10.6 mmHg,试验后分别为49.1±23.8 mmHg和23.0±13.5 mmHg;卡托普利组试验前分别为47.0±15.5 mmHg和21.7±8.4 mmHg,试验后分别为46.6±15.4 mmHg。结果可能支持这样的论点,即血管舒张作用更多地取决于肺血管变化的程度,而不是特定药物的血管舒张机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验